

Data Sharing Statement

Article Info	http://dx.doi.org/10.21037/apm-19-531	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The incidence of chemotherapy-induced FN in control and treatment group will be shared. We also found Joungal safely and effectively decreased the incidence of neutropenia and FN induced by doublet platinum-based chemotherapy in patients with lung cancer, and may have potential as a supportive care agent for patients with lung cancer
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists who are interested in this field.
8	For what type of analysis or purpose?	For analysis to evaluate the Efficacy of Joungal in Preventing Febrile Neutropenia Induced by Platinum-based Doublet Chemotherapy in Lung Cancer.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: zhangyongchang@csu.edu.cn.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.